A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications

In 2015, the World Health Organization (WHO) Expert Committee approved the addition of 16 cancer medicines to the WHO Model List of Essential Medicines (EML), bringing the total number of cancer medicines on the list to 46. This change represented the first major revision to the EML oncology section...

Descripción completa

Detalles Bibliográficos
Autores principales: Baxi, Sangita M., Beall, Reed, Yang, Joshua, Mackey, Tim K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751842/
https://www.ncbi.nlm.nih.gov/pubmed/31533850
http://dx.doi.org/10.1186/s12992-019-0497-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751842/
https://www.ncbi.nlm.nih.gov/pubmed/31533850
http://dx.doi.org/10.1186/s12992-019-0497-3

Ejemplares similares